Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05390385 · ClinicalTrials.gov registry record · NA
Acceptability and Tolerability of Ketone Supplements and Effects of BHB Concentrations in Young Adults
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT05390385: Completed NA study, sponsored by University of Alabama at Birmingham.
NCT05390385 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05390385, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Assess the acceptability and tolerability of two different commercially available ketone supplements and determine their effects on capillary blood concentrations of the ketone beta-hydroxybutyrate and glucose in young adults.
Primary Outcome
The ketone supplements being used have been described as having strong, disagreeable flavors. Therefore, the first outcome measure will be understanding how the flavors and gastrointestinal effects of both supplements may impact subjects. This outcome measure will be assessed by measuring the symptoms experienced, the time at which each symptom occurred, and the duration of each symptom using a scaled symptom questionnaire titled "Symptom Questionnaire." The questionnaire rates symptoms on an or
Interventions
- OTHER Placebo drink
- DIETARY_SUPPLEMENT KE1 5g
- DIETARY_SUPPLEMENT KE1 10g
- DIETARY_SUPPLEMENT KE4 5g
- DIETARY_SUPPLEMENT KE 10g
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2023-08-15 |
| Phase | NA |
What the finished NCT05390385 record still lists
NCT05390385 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo drink is the first listed.
NCT05390385 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05390385 about?
NCT05390385 is a clinical study titled "Acceptability and Tolerability of Ketone Supplements and Effects of BHB Concentrations in Young Adults". Assess the acceptability and tolerability of two different commercially available ketone supplements and determine their effects on capillary blood concentrations of the ketone beta-hydroxybutyrate and glucose in young adults.
What is the current status of trial NCT05390385?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2022-09-23. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT05390385?
The interventions under investigation include: Placebo drink (OTHER), KE1 5g (DIETARY_SUPPLEMENT), KE1 10g (DIETARY_SUPPLEMENT), KE4 5g (DIETARY_SUPPLEMENT), KE 10g (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05390385?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05390385's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy